welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- log in
Novo Biosciences achieves major milestones in moving trodusquemine into clinical trials
Novo Biosciences Inc., has achieved several major milestones in its mission of bringing its breakthrough drug candidate, trodusquemine (aka MSI-1436), to market as a potential regenerative medicine treatment for heart disease and Duchenne muscular dystrophy (DMD). Trodusquemine is a repurposed drug candidate that has already been shown to be well tolerated by patients.
“Trodusquemine holds significant potential for the treatment of some of our most devastating diseases,” said Kevin Strange, Ph.D., Novo’s CEO. “Our recent progress on the path toward clinical trials gives hope to the millions of patients who face limited treatment options.”
rareRelated
-
Safety Study of Flavocoxid in Duchenne Muscular DystrophyObjective of this study is to evaluate s...
-
Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, ran...Background: Duchenne muscular dystrophy...
-
DMD Gene Therapy Clinical Trial: Making a Difference by Gene Replacement (Dr. Jerry Mendell)https://www.youtube.com/watch?v=AeTqv29h...
-
Improved Muscle Function in Duchenne Muscular Dystrophy Through L-Arginine and MetforminThe purpose of the study is to show that...
-
A Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids, in Subjects With Non-ambulat...To evaluate the efficacy and safety of p...
-
A current approach to heart failure in Duchenne muscular dystrophyDuchenne muscular dystrophy (DMD) is a g...
-
CureDuchenne – Treating the Whole DiseaseDuchenne muscular dystrophy is a multifa...
-
Shape Therapeutics’s RNA Editing Gene Therapy Platform Focused on Curing Genetic DiseasesShape Therapeutics, Inc. (ShapeTx), a de...
